Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
305.30
+1.59 (0.52%)
Oct 14, 2025, 10:53 AM EDT - Market open
Bio-Rad Laboratories Revenue
Bio-Rad Laboratories had revenue of $651.60M in the quarter ending June 30, 2025, with 2.05% growth. This brings the company's revenue in the last twelve months to $2.55B, down -0.33% year-over-year. In the year 2024, Bio-Rad Laboratories had annual revenue of $2.57B, down -3.92%.
Revenue (ttm)
$2.55B
Revenue Growth
-0.33%
P/S Ratio
3.30
Revenue / Employee
$331,714
Employees
7,700
Market Cap
8.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57B | -104.70M | -3.92% |
| Dec 31, 2023 | 2.67B | -131.00M | -4.67% |
| Dec 31, 2022 | 2.80B | -120.35M | -4.12% |
| Dec 31, 2021 | 2.92B | 376.92M | 14.81% |
| Dec 31, 2020 | 2.55B | 233.97M | 10.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BIO News
- 5 weeks ago - Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc. - GlobeNewsWire
- 5 weeks ago - Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 7 weeks ago - Bio-Rad's Management to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause - Seeking Alpha
- 2 months ago - Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings - Benzinga
- 2 months ago - Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 - Business Wire
- 2 months ago - Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Bio-Rad Reports Second-Quarter 2025 Financial Results - Business Wire